The fluoroquinolones: How long will their utility last?

被引:35
作者
Bakken, JS [1 ]
机构
[1] St Lukes Infect Dis Associates, Duluth, MN 55805 USA
关键词
D O I
10.1080/00365540410019039
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Injudicious use of the fluoroquinolones may result in treatment failure, increased patient morbidity, increased health care cost, and possible patient fatality. Fluoroquinolone-resistant bacteria may also adversely impact the microbiological environment in the hospital, the local community and eventually large geographical regions. Fluoroquinolone resistance develops in a stepwise fashion, and current susceptibility testing methods and recommended MIC susceptible breakpoint values for the United States may fail to identify some bacteria that are resistant due to first step mutations at the fluoroquinolone target site gene sequences. C-8 methoxy-fluoroquinolone compounds are more active against resistant bacteria than the older compounds. Fluoroquinolone resistance relates directly to human and veterinary usage and emerging bacterial resistance poses the single greatest threat to the future survival of the fluoroquinolone drugs as an antibiotic class.
引用
收藏
页码:85 / 92
页数:8
相关论文
共 80 条
[31]   Mutant prevention concentration of gemifloxacin for clinical isolates of Streptococcus pneumoniae [J].
Hansen, GT ;
Metzler, K ;
Drlica, K ;
Blondeau, JM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (01) :440-441
[32]   Quinolone-binding pocket of DNA gyrase: Role of GyrB [J].
Heddle, J ;
Maxwell, A .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (06) :1805-1815
[33]   Management of community-acquired pneumonia in the era of pneumococcal resistance -: A report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group [J].
Heffelfinger, JD ;
Dowell, SF ;
Jorgensen, JH ;
Klugman, KP ;
Mabry, LR ;
Musher, DM ;
Plouffe, JF ;
Rakowsky, A ;
Schuchat, A ;
Whitney, CG .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (10) :1399-1408
[34]  
HO PL, 2000, J ANTIMICROB CHEMOTH, P659
[35]   Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999 [J].
Hoban, DJ ;
Doern, GV ;
Fluit, AC ;
Roussel-Delvallez, M ;
Jones, RN .
CLINICAL INFECTIOUS DISEASES, 2001, 32 :S81-S93
[36]   Mechanisms of fluoroquinolone resistance [J].
Hooper, DC .
DRUG RESISTANCE UPDATES, 1999, 2 (01) :38-55
[37]   Emerging mechanisms of fluoroquinolone resistance [J].
Hooper, DC .
EMERGING INFECTIOUS DISEASES, 2001, 7 (02) :337-341
[38]  
HOOPER DC, 2001, CLIN INFECT DIS S1, V32, P9
[39]   INVITRO ANTI-BACTERIAL ACTIVITY OF AM-715, A NEW NALIDIXIC-ACID ANALOG [J].
ITO, A ;
HIRAI, K ;
INOUE, M ;
KOGA, H ;
SUZUE, S ;
IRIKURA, T ;
MITSUHASHI, S .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1980, 17 (02) :103-108
[40]   Influence of patient age on the susceptibility patterns of Streptococcus pneumoniae isolates in North America (2000-2001):: report from the SENTRY Antimicrobial Surveillance Program [J].
Jones, RN ;
Biedenbach, DJ ;
Beach, ML .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2003, 46 (01) :77-80